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ABSTRACT
Objectives:  To determine the prevalence and to characterise Gaucher’s disease in 
terms of socio-demographic data, clinical presentation, and management as seen at 
Kenyatta National Hospital.
Design:  A retrospective record based study.
Setting: Kenyatta National Hospital, a referral and teaching hospital.
Main outcome measures:  Prevalence (number of cases seen a year), of Gaucher’s 
disease, sociodemographic data, clinical presentation, mode of diagnosis and treatment 
modalities of Gauchers disease.
Results: Nine patients were studied, four males and five females giving a prevalence 
of 0.9 cases seen a year and a M:F ratio of about 1:1.  The most common presentation 
was splenomegaly in nine (100%) cases and hepatomegaly in seven (78%) patients, 
neurological and bone symptoms were rare, in one (11%) cases and in two (22%) cases 
respectively.  Diagnosis was mainly on basis of presence of Gaucher cells in bone 
marrow and splenic aspirate as enzyme assay was unavailable.  Management was 
mainly supportive and enzyme therapy was only available for two (22%) patients.  
Anaemia was the most common complication with seven (78%) patients and one 
death occurred due to osteomyelitis.  Only four (44%) patients were followed up for 
a period of four years.
Conclusions:  Gaucher’s disease is a rare condition at the Kenyatta National Hospital 
(KNH).  The presentation of most patients is organomegaly, (hepatosplenomegaly) and 
best fits the type 1 or non-neuronopathic Gaucher’s disease.  Neurological manifestations 
are rare.  Management of this condition at the KNH is mainly supportive and enzyme 
therapy still remains out of reach for most patients. 
INTRODUCTION
Gaucher’s disease (GD) results from an inborn 
error of glycophospholipid metabolism caused 
by deficient activity of lysosomal hydrolase called 
glucocerebrosidase.  The defect causes progressive 
accumulation of glycolipid substrates, particularly 
glycosylceramide in the reticuloendothelial 
cells.  This accumulation results in infiltration 
of the bone marrow, hepatosplenomegaly and 
skeletal complications (1).  The Gaucher’s cell that 
characterises this disorder is of macrophage lineage. 
The genetic pattern is autosomal recessive and the 
sex distribution is equal (2).
 Gaucher’s disease is the most common lipid 
storage disorder and most common genetic disease 
in the Ashkenazi Jews with a prevalence of 1 per 
1,000. It is rare in the non-Jewish population with 
an estimated frequency of 1 in 40,000.  The overall 
frequency globally is about 1 in 200,000 and the 
disease has been reported in non-Jewish Caucasians 
as well as natives of Greece, India, China and Japan 
(3).  The local prevalence is unknown although 
hospital records indicate that cases are seen in our 
setting.  Similarly, data from other African countries 
is lacking.
 Clinically three distinct types are seen 
and classified on the basis of the presence and 
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progression of neurological complications.  Type 
1 or non-neuronopathic Gaucher’s disease is the 
most common clinical variant of the disease.  It is 
particularly prevalent in Ashkenazi Jews in whom it 
may affect up to 1 in 450 individuals.  This may be the 
prevalent clinical variant in our setting and studies 
are currently in progress to elucidate the nature and 
severity of symptoms in patients with mild disease. 
Type 2, or acute neuronopathic Gaucher’s disease, 
is a rare, pan-ethnic variant that characteristically 
presents in early infancy (average age three months) 
with obvious severe CNS involvement (e.g. Seizures, 
trismus, strabismus, psychomotor retardation, 
spasticity, sucking and swallowing difficulties) with 
hepatosplenomegaly. It progresses rapidly to death 
before the age of two to three years and has no ethnic 
predilection.  Type 3, or subacute neuronopathic 
Gaucher’s disease, classically presents in middle 
childhood as a progressive neurodegenerative 
disorder (type 3a); however, it may also present with 
severe, ultimately fatal, visceral disease.
 The clinical presentation of this disorder has not 
been studied in our setting.  Owing to its non-specific 
presentation, (hepatosplenomegaly which is common 
in many other tropical conditions) diagnosis may 
be missed due to the low index of suspicion.  This 
disease is amenable to treatment albeit costly and 
enzyme replacement has been shown to be effective 
and safe.  Hospital records document one to two cases 
seen annually in the paediatric referral wards.
 The measurement of glucocerebrosidase activity 
in peripheral blood leukocytes, skin fibroblasts, 
amniocytes, or chorionic villi remains the most 
universally effective method in the diagnosis of 
GD with heterozygotes having approximately one 
half of the normal enzyme activity.  The presence of 
Gaucher’s cells in the bones and liver biopsy is almost 
always pathognomonic of GD (1,4,5).  Molecular 
diagnosis is feasible in some circumstances.  In our 
setting, clinical symptomatology and the presence 
of Gaucher’s cells in bone marrow or spleen are 
the mainstay of diagnosis.  Enzyme assays are not 
available locally. 
 Treatment with an acid beta glucosidase 
prepared with recombinant DNA technology or 
obtained from the placenta offers considerable clinical 
improvement with enhanced quality of life (3). This 
therapy decreases liver and spleen size, reduces some 
skeletal abnormalities, and successfully reverses other 
manifestations of the disorder including abnormal 
blood counts.  Bone marrow transplantation has 
cured a small number of patients and steroids have 
been reported to alleviate symptomatology during 
crisis (6,7). Splenectomy may be performed for 
thrombocytopenia (4). Future treatment may include 
gene therapy.
MATERIALS AND METHODS 
Case notes of all patients diagnosed with Gaucher’s 
disease on basis of presence of Gaucher’s cells in bone 
marrow or splenic aspirates between the period of 
January 1995 and December 2005 were examined and 
relevant data (socio-demographic, presentation, mode 
of diagnosis, management modalities and outcome) 
were collated on to a structured form and analysed.
RESULTS
There were nine cases of Gaucher’s disease of whom 
four (44%) were male and five (56%) were female 
giving a male to female ratio of 1:1.25. The ages ranged 
from four months to seven years with a mean of four 
years. Of the patients seen six (67%) hailed from the 
Eastern province of Kenya and four (44%) from the 
Central province. 
 The majority, six (67%) were of Kikuyu ethnicity 
while the remaining three (33%) were of Embu, 
Meru and Kamba ethnicity. At the time of diagnosis, 
symptoms had been present for a duration of one 
month to two years.
 The age at presentation ranged from one year 
three months to six years with a mean of four years 
three months.  The clinical features were as follows 
in order of frequency; splenomegaly in nine (100%), 
hepatomegaly in seven (78%), failure to thrive seven 
(78%), pallor seven (78%), lymphadenopathy six (67%), 
fever four (44%), bleeding two (22%) and bone fracture 
two (22%). Lethargy, neurological symptoms and 
oedema all occurred only in one (11%) patient each and 
jaundice and bone pain were not among the presenting 
clinical features. The neurological presentation was 
in the form of delayed milestones in a patient with 
failure to thrive who was at the time seven years old. 
Spleen enlargement ranged from 6 – 24 cm while the 
liver enlargement was smaller 4 – 11 cm  (Table 1).
 
Table 1
Clinical features of Gaucher’s disease 
Clinical feature No. (%)
Organomegaly 
 Spleen 9 100
 Liver 7 78
 Lymphadenopathy 6 67




 Pain  0 0
 Fracture 2 22
 Osteoporosis 1 11
 CNS 1 11
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The diagnosis of Gaucher’s disease was made on 
bone marrow aspirate in eight (89%) of the cases 
and one (11%) on splenic aspirate. No patient had 
enzyme assays performed for confirmation of the 
diagnosis. Enzyme therapy was administered in only 
two (22%) of the patients. The other patients received 
only supportive care which consisted of red blood 
cells, fresh frozen plasma and platelet transfusions, 
antibiotics, anti-tuberculosis treatment, analgesics, and 
haematinics. Traction and plaster of paris application 
were performed in the two patients with fracture neck 
of femur and fracture femur respectively. 
 In the haematological findings, seven (78%) had 
anaemia  (haemoglobin 4 to 10.9 g/dl), 3 (33%) had 
thrombocytopaenia (platelets 94 to 149 x 109 /L) and 
only one (11%) had leucopaenia (WBC 2 x 109/L). 
Only one (11%) patient had osteoporosis. The liver 
enzymes were normal in all nine (100%) patients but 
two (22%) had a raised International Normalised 
Ratio (INR) (Table 2). 
Table 2
Laboratory features of Gaucher’s disease 
 Laboratory feature No. (%)
Total Blood Count
 Anaemia 7 78
 Thrombocytopenia 4 44
 Leucopenia 1 11
Radiological imaging
 Fracture  2 22
 Osteoporosis 1 11
 Respiratory infection 1 11
Raised acid phosphatase 3 33
There was one death which was secondary to 
osteomyelitis. Only four (44%) of the patients were 
followed up and this was for a duration of two to 
four years.
DISCUSSION
Gaucher’s disease has been divided into three main 
types based on the clinical presentation. Most of the 
patients (89%) did not have neurological symptoms 
and had presented at the age of one year and beyond. 
These most likely had type 1 disease which is by 
far the most common variant of the disease and is 
particularly prevalent among the Ashkenazi Jews 
(6,7).There was only one patient aged seven years 
with neurological symptoms which had manifested 
as delayed milestones of infancy. This patient most 
likely had type 2, the neuropathic disease which 
presents in early infancy (8,9). 
 Gaucher’s disease is inherited as an autosomal 
recessive trait and males and females are equally 
affected (2). This was illustrated in this study where 
the male to female ratio was 1:1.25. Our patients 
were all either from the Eastern province (67%) or 
the Central province and the majority (67%) were 
of Kikuyu ethnicity. This is most likely due to the 
location of the national referral hospital which is 
within easy reach of the Eastern and Central provinces 
where these ethnic groups are found. However, the 
possibility of a genetic predisposition in this group 
cannot be excluded and there is need for further 
genetic studies in this population.
 Confirmation of Gaucher ’s disease is by 
demonstration of reduced levels of the enzyme 
glucocerebrosidase, however, this technique is still 
unavailable in the hospital. Diagnosis, therefore, 
rested on the finding of the Gaucher’s cell in either 
the bone marrow or the spleen. Gaucher’s - like cells 
may occur in other conditions primarily neoplastic 
or haematologic disorders associated with increased 
red cell or leucocytes turnover like leukaemia 
especially chronic granulocytic leukaemia and hairy 
cell leukaemia, Hodgkin’s, Non Hodgkin’s disease, 
lymphoma. These cells are also found in thallasaemia 
and acquired immunodeficiency syndrome (10). 
Most of these conditions present with a clinical 
picture that is similar to that of Gaucher’s disease 
with splenomegaly, hepatomegaly, fever, lethargy, 
anaemia and bleeding. 
 In all three types of the disease, splenomegaly 
is usually the earliest sign and is often complicated 
by hypersplenism leading to  thrombocytopaenia 
with bleeding diasthesis, anaemia and leucopaenia. 
Hepatomegaly is another frequent sign of Gaucher’s 
disease but is usually milder than the splenomegaly. 
All our patients had splenomegaly as a feature while 
78% had hepatomegaly. The hepatomegaly (range 
4-12cm) was typically milder than the splenomegaly 
(range 6-24cm) (11).
 Zimran et al (12) studied 53 patients who were 
mostly in their early adulthood with a mean age of 
33 years. He found that the most common presenting 
symptom was bleeding related to splenomegaly and 
thrombocytopaenia and that the chronic symptoms 
evaluated for over a period of 20 years after the 
diagnosis were mainly skeletal.
 Haematologic abnormalities, a consequence of 
splenic sequestration and over activity of Gaucher’s 
cell infiltration of the bone marrow and displacement 
of haematopoetic elements, comprise some of the 
most common problems in Gaucher’s disease (11,13). 
Mild to severe thrombocytopaenia (<20,000/µL) 
and normocytic, normochromic anaemia are the 
most frequent such abnormalities. Erythrocyte and 
placelet survival is decreased, and coagulopathy and 
haemorrhagic diathesis may develop (13).
 In this study seven (78%) had anaemia four 
(44%) had thrombocytopaenia and only one (11%) 
had leucopaenia. Bleeding was rare and was seen 
only in two patients (22%). 
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 Skeletal disease in Gaucher’s disease is common 
occurring in 50 – 100% of cases (11,14,15). The 
aetiology is not fully known, but a key pathogenetic 
process appears to be the progressive infiltration 
and replacement of bone marrow trabecular bone by 
Gaucher’s cells. Skeletal complications can be divided 
into five major categories: failure of remodeling, 
osteopaenia, osteonecrosis leading to fractures, 
osteosclerosis, and bone crises, acute episodes of 
excruciating pain resembling those in sickle cell 
anaemia (16). Skeletal disease in our population 
was less common than in the reported series, 30%. 
Children and adolescents with Gaucher’s disease 
sometimes suffer growth stunting and a pubertal 
delay as was seen in our series where seven (78%) 
were underweight.  Our patients were evaluated in a 
referral centre and therefore the data obtained needs 
to be interpreted with great caution when applying 
to the general population which most probably 
contains a greater population of very mild cases. 
Enzyme replacement therapy for type one disease has 
been available for the last ten years and is known to 
result in clinical improvement with enhanced quality 
of life, dramatic reduction of hepatosplenomegaly 
within one to three years and resolution of both the 
haematologic and splenic derangements (3,17-20). 
In our study only two (22%)   of the patients were 
started on enzyme replacement therapy due to its 
prohibitive cost. The two, a girl and her sibling, were 
at the time spending 800USD and 400USD respectively 
per month for this treatment.
In conclussion, Gaucher’s’s disease is a rare disease 
in paediatric practice at the Kenyatta National 
Teaching and Referral Hospital.  The most common 
presentation is hepatosplenomegaly.  With most 
patients falling in the category of type I Gaucher’s 
disease.  Neurological and skeletal disease appear to 
be a rare presentation in our population.  Enzyme 
replacement therapy still remains out of reach for 
most patients.   
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